title: [Effects of Panax notoginseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice].
abstract: OBJECTIVE
  To observe the effects of Panax notoginseng saponins (PNS) on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in a type 2 diabetic KK-Ay gene mice model.
  
  
  METHODS
  All animals were divided into 4 groups: Normal control group (C57BL/6J mice) were treated by NS 10 mL/kg, KK-Ay mice were subdivided into 3 groups as DM administrated NS 10 mL/kg, PNS 50 mg/kg, PNS 200 mg/kg respectively. All the animals received daily intraperitoneal injections for 30 days consecutively. All of these following items were determined as the effect of PNS: fasting plasma glucose levels (FPG), intraperitoneal glucose tolerance, body weight, food intake, insulin resistance index (IRI), serum insulin, triglyceride (TG), cholesterol (CH) levels and contribution of glomerulus injury.
  
  
  RESULTS
  On the 12th, 22nd and 30th day, PNS-treated group had significantly lower FPG and low body weight incremental percentage. After a 12-day treatment, glucose tolerance was significantly improved. On the 30th day the serum IRI and TG levels of PNS-treated group decreased significantly, and the development of the mice glomerular lesions was prevented significantly. All of these showed a dose-effect relationship.
  
  
  CONCLUSIONS
  PNS has the effects of anti-diabetes, anti-obese and prevention from kidney pathological changes in type 2 diabetic KK-Ay mice.
authors.affiliation: Department of pharmacology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. 11505011@163.com
authors.forename: Chang-Yong
authors.initials: CY
authors.lastname: Yang
authors.forename: Zhen-Guo
authors.initials: ZG
authors.lastname: Xie
authors.forename: Wei-Bo
authors.initials: WB
authors.lastname: Cheng
authors.forename: Xing
authors.initials: X
authors.lastname: Jiang
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Chen
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000517:prevention & control; D005894:Panax / Q000737:chemistry*; D018517:Plant Roots / Q000737:chemistry; D011897:Random Allocation; D012503:Saponins / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D019440:Anti-Obesity Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D012503:Saponins